Objective The aim of the study was to evaluate the evolution of plasma adipokines and
lipodystrophy in protease inhibitor‐naïve vertically HIV‐infected children on highly active …

Background Lipodystrophy is common in HIV-infected patients receiving protease inhibitors
(PIs), stavudine, and zidovudine. Adipocytokines may be altered in lipodystrophy. We …

Objectives To estimate prevalence of body fat redistribution and dyslipidaemia in HIV-
infected children and to assess associated risk factors, ultimately to inform the definition of …

Objective The aim of this study was to assess the changes in body fat distribution and lipid
abnormalities in a population of HIV-infected children and adolescents followed in one …

Objectives: To estimate the prevalence of and identify risk factors for lipodystrophy syndrome
(LS) and body fat abnormality in a population of HIV-infected children and adolescents …

Objective An antiretroviral regimen based on lamivudine+ stavudine+ protease inhibitor
impairs peripheral fat accrual in HIV-infected children and adolescents. We assess the effect …

In this study we assessed the prevalence of fat redistribution and metabolic disorders in a
population of HIV-infected children on antiretroviral treatment. To make associations with …

Background Combined use of dual-energy X-ray absorptiometry (DXA) and magnetic
resonance imaging (MRI) allows a precise estimate of regional body composition and intra …

Objective To assess the metabolic drug toxicities of first-line, World Health Organization
(WHO)-recommended generic highly active antiretroviral therapy (HAART) regimens, to …

Objectives HIV‐related lipodystrophy is a syndrome of adipose tissue redistribution,
dyslipidaemia and insulin resistance. Combination antiretroviral therapy (CART) is a key risk …